Meet us at CPHI Frankfurt 2025

As the pharmaceutical industry stands at the intersection of innovation and urgency, the need for transformative solutions has never been more critical

With our groundbreaking 3D printing technology, we’re redefining how medicines are made, delivered, and experienced. Our platform enables rapid, scalable production of highly customizable treatments, helping manufacturers respond faster to patient needs while enhancing safety and efficacy.

Our technology enables:

Continuous, high-efficiency production with reduced risk
Rapid prototyping and clinical supply development for faster trial decisions
Accelerated market entry through flexible, scalable platforms
Enhanced responsiveness to clinical trial changes
Precise powder handling for novel dosage forms at clinical and commercial scale

Visit Aprecia at CPHI 2025 to discover how we’re transforming pharma

📍Booth 4.1H38

🔍 Explore our latest advancements with our in-blister binder jet technology

🤝 Connect with our experts shaping the future of drug delivery

🚀 See how 3D printing is unlocking new possibilities for solubility enhancement

Don’t miss your chance to be part of the next wave of pharmaceutical innovation. Let’s build the future together.

Attend Our Presentations

Current and Future Applications of 3D Printing in Pharmaceutical Dosage Form Development

Advanced manufacturing technologies like 3D printing (3DP) are attracting growing interest across the pharmaceutical sector due to their potential to address drug delivery challenges, reduce development time, enhance quality via process analytical technologies (PAT), enable personalised medicine, automate compounding, and support distributed manufacturing models.

Aprecia led the way by securing FDA approval for the first and only 3DP drug product. Since then, ongoing innovations and alternative 3DP approaches have expanded the field.

Michael Gosselin, VP, Pharmaceutical Development, Aprecia Pharmaceuticals
Wednesday, October 29, 2025 4:10 PM to 4:30 PM · 20 min. (CET) Manufacturing 5.0

Accelerating Innovation by combining 3D Printing and Solubility Enhancement

As the pharmaceutical industry embraces advanced manufacturing, the fusion of 3D printing and mesoporous silica loading presents a transformative opportunity for tackling solubility challenges in drug development. This session, led by experts from Merck KGaA (Darmstadt, Germany) and Aprecia Pharmaceuticals, explores how Parteck® SLC—a high-surface-area silica—can be combined with additive manufacturing to enhance bioavailability, streamline formulation, and accelerate clinical timelines. Attendees will gain insights into Aprecia’s binder jetting technologies using SoluPrint™ with in-blister tablet printing platforms. Real-world case studies demonstrate the potential for personalized, scalable, and GMP-compliant production. Join us to discover how these synergistic technologies are reshaping the future of oral dosage forms.

Kyle Smith, President & Chief Operating Officer, Aprecia Pharmaceuticals
Dr. Thomas Kipping, Associate Director, Head of Enabling Technologies, Merck KGaA, Darmstadt
Thursday, October 30, 2025, 1:45 PM to 2:10 PM · 25 min. (CET)
Hall 4.1 – 4.1L8